Introduction
This monograph on lung cancer has been prepared to provide information on patterns of practice to those directly involved in the provision of care to lung cancer patients. As well, it should be helpful to those who are responsible for managing aspects of the cancer system that impact on the care that lung cancer patients receive across the province of Ontario. The practice patterns are shown against the backdrop of the evidence-based guidelines developed by the Lung Disease Site Group of Cancer Care
Ontario's Program in Evidencebased Care. In addition to information on patterns of practice, this monograph provides information on the timeliness of access to care, as well as a brief overview of the incidence and mortality of lung cancer, and the trends in the main risk factor for developing lung cancer, namely smoking. In brief, it provides a snapshot of the quality of care for lung cancer patients in the province of Ontario. It is hoped that this monograph will assist those responsible for care delivery to achieve the best possible results for patients with a diagnosis of lung cancer.
Incidence of Lung Cancer
Lung cancer is the most common cause of death due to cancer in Canada. In 2003, it is estimated that there will be 21,100 new cases and 18,800 deaths from lung cancer. In Ontario, it is estimated that there will be 7,500 new cases and 6,300 deaths from lung cancer. Figure 1 shows the incidence of lung cancer by gender over the past 10 years. Although the overall incidence is higher in men, there has been a steady decrease in the incidence of lung cancer in men in the past 10 years. In contrast, the incidence rate among women has been steadily increasing.
CLINICAL FOCUS ON LUNG CANCER Risk Factors
Lung cancer is the most preventable of all human cancers. Cigarette smoking is the main cause of lung cancer and it should be no surprise to anyone that changes in the incidence of lung cancer run parallel to changes in smoking habits. Individuals who have been smoking for the past several decades are the ones now being diagnosed with lung cancer. Twenty years ago there were record numbers of women, including teenagers, who were smoking regularly. The number of men smoking at that time, in all age groups, had begun to decline. The trends in smoking rates among men and women over the past decade are shown in Figure 2 and Figure 3 . As fewer people are smoking today, it is anticipated that lung cancer rates will be lower in the future. Nonetheless, aggressive anti-smoking measures must continue, as the proportion of the population smoking is still approximately 19%. Factors helping to reduce smoking include strict anti-smoking bylaws, cigarette taxation, smoking cessation programs, and school and public education programs. Figure 4 shows the mortality rate (death rate per 100,000 population) from lung cancer for both men and women over the past decade. The graph for mortality is similar to that for incidence, in that men show a decline in mortality, whereas women show an increasing mortality rate. 
Mortality from Lung Cancer
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CLINICAL FOCUS ON LUNG CANCER
Role of Palliative Care
Palliative care plays a very important role in the management of lung cancer patients because, as noted in the section on lung cancer mortality, the five-year survival of lung cancer patients is less than 15%. 
Centre Weeks
Hamilton Regional Cancer Centre 3.9
Kingston Regional Cancer Centre 2.7
London Regional Cancer Centre 1.9
Northeastern Ontario Regional Cancer Centre 3.9
Northwestern Ontario Regional Cancer Centre 2.9
Ottawa Regional Cancer Centre 3.0 14 15
Glossary of Terms
Adjuvant chemotherapy
The use of anti-cancer drugs after surgery to decrease the chance of the cancer coming back.
Adjuvant therapy
A treatment method used in addition to the primary therapy; used to increase the effectiveness of treatment.
Age-standardized rate
The number of new cases of cancer or cancer deaths per 100,000 that a population would have if it had a standard age structure. Standardization is necessary when comparing several populations that differ with respect to age because age has such a powerful influence on mortality and morbidity indicators.
Age-specific rate
The number of new cases of cancer or cancer deaths during the year, expressed as a rate per 100,000 persons in a given age group.
Chemotherapy
A drug or combination of drugs used to kill cancer cells and fight cancer.
Combination chemotherapy
Treatment using two or more anti-cancer medications.
Combined modality therapy
Two or more types of treatment are given either at the same time or in sequence; may include combinations of radiation, chemotherapy, surgery, or others.
Five-year relative survival
A measure of the reduction in life expectancy due to a diagnosis of cancer. Relative survival is estimated from life tables as the ratio of the observed survival of cancer cases five years after diagnosis to the expected survival of individuals of the same age in the general population. 
Locally advanced cancer
Cancer that has spread only to nearby tissues or lymph nodes.
Lymph nodes
Small bean-shaped organ that acts as a filter to collect bacteria and other foreign substances from the lymphatic system to be processed by the immune system.
Metastasis
The spread of cancer cells from the original site to other parts of the body.
Modality
A type or kind of treatment (surgery, chemotherapy, radiotherapy).
Multimodality therapy
Therapy that combines more than one method of treatment such as chemotherapy and radiation.
Neoadjuvant therapy
Therapy given before the primary treatment to treat a cancer to improve the effectiveness of the primary treatment; neoadjuvant therapy can be chemotherapy or radiation therapy.
Non-small cell lung cancer
The most common histological type of lung cancer; includes adenocarcinoma, squamous cell carcinomas, large cell anaplastic and bronchial alveolar carcinomas.
Ontario Cancer Registry
The population-based database that includes information on all diagnoses of cancer reported in Ontario since 1964. It includes limited data about diagnosis (date, type of cancer), death (date, cause), treatment, and the individual (date of birth, sex, census division of residence at diagnosis/death) for all cancer patients. It does not include data on risk factors, stage, grade, or non-melanoma skin cancers.
Prevalence
The total number of active cancer cases in the population at the current moment in time.
Radiation treatment
X-ray treatment that damages or kills cancer cells.
Regimen
The plan that outlines the dosage, schedule and duration of treatment.
Regional involvement
The spread of cancer from its original site to nearby surrounding areas.
Risk factors
Anything that may increase a person's chance of developing cancer. It may be an activity, such as smoking, diet, family history, environmental agents or many other things.
Side effect
An effect on the body caused by cancer treatment other than the effect on the cancer; also called adverse reaction.
Small cell lung cancer
A histological type of lung cancer characterized by rapid growth clinically and characteristic small cells as seen under the microscope.
Staging
A method to describe the size of a tumour and the extent of its spread.
Standard treatment
Treatment that has been proven effective and is commonly used.
Surgical resection
Removing tissue from the body through a surgical procedure.
Systemic disease
Disease that affects the whole body rather than only an organ.
Systemic treatment
Treatment that reaches cells all over the body by travelling through the bloodstream.
Three-year moving average
Rate calculated using the sum of the new cases of cancer or cancer deaths for a three-year period and the population estimates for those same years. Three-year moving average rates are shown on all graphs describing trends in order to smooth out annual fluctuation.
Tumour histology
The type of cancer as classified by its appearance under the microscope.
Unresectable
Cannot be surgically removed.
